Nkarta, Inc. (NKTX) 10-Year Financial Performance & Capital Metrics

NKTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutNkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Show more

Revenue $0
EBITDA -$119M +5.4%
Net Income -$109M +7.4%
EPS (Diluted) -1.60 +33.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -31.94% +12.3%
ROIC -24.31% +7.9%
Debt/Equity 0.20 -39.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.3x book value

✗Weaknesses

✗Shares diluted 38.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM7.23%

EPS CAGR

10Y-

5Y-

3Y-

TTM26.6%

ROCE

10Y Avg-36.04%

5Y Avg-30.78%

3Y Avg-32.22%

Latest-30.6%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	6.55M	115.39K	0	0	0	0	0
Revenue Growth %	-	-0.98%	-1%	-	-	-	-
Cost of Goods Sold+	4.25M	17.22K	0	0	0	5.87M	0
COGS % of Revenue	0.65%	0.15%	-	-	-	-	-
Gross Profit+	2.3M	98.17K	0	0	0	-5.87M	0
Gross Margin %	0.35%	0.85%	-	-	-	-	-
Gross Profit Growth %	-	-0.96%	-1%	-	-	-	1%
Operating Expenses+	6.91M	22.46M	51.51M	86.43M	118.95M	125.78M	128.19M
OpEx % of Revenue	1.05%	194.69%	-	-	-	-	-
Selling, General & Admin	2.65M	5.25M	15.29M	23.02M	28.06M	34.88M	31.45M
SG&A % of Revenue	0.41%	45.47%	-	-	-	-	-
Research & Development	4.25M	17.22M	36.22M	63.41M	90.9M	90.9M	96.74M
R&D % of Revenue	0.65%	149.21%	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-356.45K	-22.35M	-51.51M	-86.43M	-118.95M	-131.65M	-128.19M
Operating Margin %	-0.05%	-193.69%	-	-	-	-	-
Operating Income Growth %	-	-61.7%	-1.3%	-0.68%	-0.38%	-0.11%	0.03%
EBITDA+	-173.24K	-21.8M	-50.72M	-84.67M	-116.32M	-125.78M	-119.04M
EBITDA Margin %	-0.03%	-188.89%	-	-	-	-	-
EBITDA Growth %	-	-124.81%	-1.33%	-0.67%	-0.37%	-0.08%	0.05%
D&A (Non-Cash Add-back)	183.21K	553.28K	786K	1.76M	2.64M	5.87M	9.15M
EBIT	-274.5K	-20.6M	-51.51M	-86.43M	-118.95M	-126.35M	-128.19M
Net Interest Income+	81.95K	-169K	313K	370K	0	14.11M	19.32M
Interest Income	81.95K	304K	313K	370K	5.59M	14.11M	19.32M
Interest Expense	0	473K	0	0	5.59M	0	0
Other Income/Expense	81.95K	1.27M	-39.85M	354K	5.12M	14.15M	19.4M
Pretax Income+	-274.5K	-21.08M	-91.36M	-86.08M	-113.84M	-117.5M	-108.79M
Pretax Margin %	-0.04%	-182.66%	-	-	-	-	-
Income Tax+	0	1.81M	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-274.5K	-21.08M	-91.36M	-86.08M	-113.84M	-117.5M	-108.79M
Net Margin %	-0.04%	-182.66%	-	-	-	-	-
Net Income Growth %	-	-75.78%	-3.33%	0.06%	-0.32%	-0.03%	0.07%
Net Income (Continuing)	-274.5K	-21.08M	-91.36M	-86.08M	-113.84M	-117.5M	-108.79M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-2.55	-1.59	-2.62	-2.61	-2.40	-1.60
EPS Growth %	-	-	0.38%	-0.65%	0%	0.08%	0.33%
EPS (Basic)	-0.01	-2.55	-1.59	-2.62	-2.61	-2.40	-1.60
Diluted Shares Outstanding	50.27M	8.98M	31.8M	32.86M	43.63M	49.01M	67.87M
Basic Shares Outstanding	50.27M	8.98M	31.8M	32.86M	43.63M	49.01M	67.87M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.23M	37.47M	318.83M	245.78M	360.69M	253.07M	273.34M
Cash & Short-Term Investments	7.87M	36.99M	314.91M	238.09M	352.14M	248.19M	267.35M
Cash Only	7.87M	20.61M	96.69M	60.82M	37.49M	31.04M	27.87M
Short-Term Investments	0	16.38M	218.22M	177.27M	314.65M	217.15M	239.48M
Accounts Receivable	150K	0	0	0	1.3M	200K	200K
Days Sales Outstanding	8.36	-	-	-	-	-	-
Inventory	117.29K	0	0	0	0	0	0
Days Inventory Outstanding	10.07	-	-	-	-	-	-
Other Current Assets	94.42K	66.51K	1.34M	3.15M	1.63M	1.42M	2.54M
Total Non-Current Assets+	1.38M	10.95M	18.82M	28.12M	112.25M	125.81M	227.87M
Property, Plant & Equipment	1.29M	10.22M	17.86M	24.53M	107.66M	119.28M	110.67M
Fixed Asset Turnover	5.09x	0.01x	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	89.81K	268.54K	0	0	2.74M	2.74M	110.39M
Other Non-Current Assets	0	455.08K	960K	3.59M	1.85M	3.8M	6.8M
Total Assets+	9.61M	48.41M	337.65M	273.9M	472.94M	378.88M	501.2M
Asset Turnover	0.68x	0.00x	-	-	-	-	-
Asset Growth %	-	4.04%	5.97%	-0.19%	0.73%	-0.2%	0.32%
Total Current Liabilities+	2.08M	8.21M	8.83M	12.94M	22.05M	23.33M	18.92M
Accounts Payable	367.17K	1.88M	1.18M	1.11M	1.76M	3.67M	638K
Days Payables Outstanding	31.52	39.9K	-	-	-	227.93	-
Short-Term Debt	0	0	0	0	4.25M	0	0
Deferred Revenue (Current)	0	1000K	0	0	0	0	0
Other Current Liabilities	408.44K	-857.45K	117K	96K	9.35M	6.72M	254K
Current Ratio	3.96x	4.56x	36.10x	18.99x	16.36x	10.85x	14.45x
Quick Ratio	3.91x	4.56x	36.10x	18.99x	16.36x	10.85x	14.45x
Cash Conversion Cycle	-13.09	-	-	-	-	-	-
Total Non-Current Liabilities+	12.92M	65.68M	7.6M	9.99M	78.69M	82.27M	74.31M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	5.78M	7.52M	9.97M	78.69M	82.27M	74.22M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	12.92M	59.9M	82K	18K	0	0	87K
Total Liabilities	15M	73.89M	16.43M	22.94M	100.73M	105.6M	93.23M
Total Debt+	12.71M	7.3M	8.92M	12.46M	82.93M	88.34M	80.27M
Net Debt	4.84M	-13.31M	-87.77M	-48.36M	45.44M	57.3M	52.4M
Debt / Equity	-	-	0.03x	0.05x	0.22x	0.32x	0.20x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-47.25x	-	-	-21.29x	-	-
Total Equity+	-5.4M	-25.48M	321.22M	250.97M	372.21M	273.29M	407.98M
Equity Growth %	-	-3.72%	13.61%	-0.22%	0.48%	-0.27%	0.49%
Book Value per Share	-0.11	-2.84	10.10	7.64	8.53	5.58	6.01
Total Shareholders' Equity	-5.4M	-25.48M	321.22M	250.97M	372.21M	273.29M	407.98M
Common Stock	123	160	3K	3K	5K	5K	7K
Retained Earnings	-5.58M	-26.66M	-118.02M	-204.1M	-317.93M	-435.43M	-544.22M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-244.75K	-2.14K	3K	-150K	-679K	8K	674K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.18M	-18.37M	-43.51M	-67.93M	-57M	-86.16M	-99.7M
Operating CF Margin %	-0.79%	-159.18%	-	-	-	-	-
Operating CF Growth %	-	-2.54%	-1.37%	-0.56%	0.16%	-0.51%	-0.16%
Net Income	-274.5K	-21.08M	-91.36M	-86.08M	-113.84M	-117.5M	-108.79M
Depreciation & Amortization	183.21K	401K	786K	1.76M	2.64M	5.87M	2.24M
Stock-Based Compensation	182.51K	947K	6.75M	14.46M	16.86M	17.2M	16.73M
Deferred Taxes	0	0	738K	3.24M	0	0	0
Other Non-Cash Items	548.94K	-818K	40.41M	337K	3.61M	-2.65M	2.29M
Working Capital Changes	-5.28M	2.18M	-828K	-1.64M	33.74M	10.93M	-12.16M
Change in Receivables	-14.82K	-463.26K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	689.71K	2.64M	2.82M	2.79M	2.76M	4.22M	-4.47M
Cash from Investing+	-757.88K	-18.3M	-210.08M	32.53M	-184.69M	79.02M	-129.56M
Capital Expenditures	-757.88K	-1.93M	-7.51M	-5.03M	-47.11M	-28.15M	-4.41M
CapEx % of Revenue	0.12%	16.71%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	-202.57K	37.56K	-137.58K	0	0
Cash from Financing+	87.49K	49.58M	329.82M	1.2M	219.01M	691K	226.08M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	87.49K	-43.5M	-63.92M	0	1.84M	0	1.01M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-5.94M	-20.3M	-51.02M	-72.95M	-104.11M	-114.31M	-104.11M
FCF Margin %	-0.91%	-175.89%	-	-	-	-	-
FCF Growth %	-	-2.42%	-1.51%	-0.43%	-0.43%	-0.1%	0.09%
FCF per Share	-0.12	-2.26	-1.60	-2.22	-2.39	-2.33	-1.53
FCF Conversion (FCF/Net Income)	18.88x	0.87x	0.48x	0.79x	0.50x	0.73x	0.92x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-61.79%	-30.09%	-36.53%	-36.41%	-31.94%
Return on Invested Capital (ROIC)	-	-	-39.69%	-29.73%	-28.77%	-26.39%	-24.31%
Gross Margin	35.08%	85.08%	-	-	-	-	-
Net Margin	-4.19%	-18265.66%	-	-	-	-	-
Debt / Equity	-	-	0.03x	0.05x	0.22x	0.32x	0.20x
Interest Coverage	-	-47.25x	-	-	-21.29x	-	-
FCF Conversion	18.88x	0.87x	0.48x	0.79x	0.50x	0.73x	0.92x
Revenue Growth	-	-98.24%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Nkarta, Inc. (NKTX) grew revenue by 0.0% over the past year. Growth has been modest.

Nkarta, Inc. (NKTX) reported a net loss of $102.6M for fiscal year 2024.

Dividend & Returns

Nkarta, Inc. (NKTX) has a return on equity (ROE) of -31.9%. Negative ROE indicates the company is unprofitable.

Nkarta, Inc. (NKTX) had negative free cash flow of $93.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Nkarta, Inc. (NKTX) 10-Year Financial Performance & Capital Metrics

NKTX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$119M +5.4%
Net Income -$109M +7.4%
EPS (Diluted) -1.60 +33.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -31.94% +12.3%
ROIC -24.31% +7.9%
Debt/Equity 0.20 -39.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.3x book value

✗Weaknesses

✗Shares diluted 38.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM7.23%

EPS CAGR

10Y-

5Y-

3Y-

TTM26.6%

ROCE

10Y Avg-36.04%

5Y Avg-30.78%

3Y Avg-32.22%

Latest-30.6%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	6.55M	115.39K	0	0	0	0	0
Revenue Growth %	-	-0.98%	-1%	-	-	-	-
Cost of Goods Sold+	4.25M	17.22K	0	0	0	5.87M	0
COGS % of Revenue	0.65%	0.15%	-	-	-	-	-
Gross Profit+	2.3M	98.17K	0	0	0	-5.87M	0
Gross Margin %	0.35%	0.85%	-	-	-	-	-
Gross Profit Growth %	-	-0.96%	-1%	-	-	-	1%
Operating Expenses+	6.91M	22.46M	51.51M	86.43M	118.95M	125.78M	128.19M
OpEx % of Revenue	1.05%	194.69%	-	-	-	-	-
Selling, General & Admin	2.65M	5.25M	15.29M	23.02M	28.06M	34.88M	31.45M
SG&A % of Revenue	0.41%	45.47%	-	-	-	-	-
Research & Development	4.25M	17.22M	36.22M	63.41M	90.9M	90.9M	96.74M
R&D % of Revenue	0.65%	149.21%	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-356.45K	-22.35M	-51.51M	-86.43M	-118.95M	-131.65M	-128.19M
Operating Margin %	-0.05%	-193.69%	-	-	-	-	-
Operating Income Growth %	-	-61.7%	-1.3%	-0.68%	-0.38%	-0.11%	0.03%
EBITDA+	-173.24K	-21.8M	-50.72M	-84.67M	-116.32M	-125.78M	-119.04M
EBITDA Margin %	-0.03%	-188.89%	-	-	-	-	-
EBITDA Growth %	-	-124.81%	-1.33%	-0.67%	-0.37%	-0.08%	0.05%
D&A (Non-Cash Add-back)	183.21K	553.28K	786K	1.76M	2.64M	5.87M	9.15M
EBIT	-274.5K	-20.6M	-51.51M	-86.43M	-118.95M	-126.35M	-128.19M
Net Interest Income+	81.95K	-169K	313K	370K	0	14.11M	19.32M
Interest Income	81.95K	304K	313K	370K	5.59M	14.11M	19.32M
Interest Expense	0	473K	0	0	5.59M	0	0
Other Income/Expense	81.95K	1.27M	-39.85M	354K	5.12M	14.15M	19.4M
Pretax Income+	-274.5K	-21.08M	-91.36M	-86.08M	-113.84M	-117.5M	-108.79M
Pretax Margin %	-0.04%	-182.66%	-	-	-	-	-
Income Tax+	0	1.81M	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-274.5K	-21.08M	-91.36M	-86.08M	-113.84M	-117.5M	-108.79M
Net Margin %	-0.04%	-182.66%	-	-	-	-	-
Net Income Growth %	-	-75.78%	-3.33%	0.06%	-0.32%	-0.03%	0.07%
Net Income (Continuing)	-274.5K	-21.08M	-91.36M	-86.08M	-113.84M	-117.5M	-108.79M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-2.55	-1.59	-2.62	-2.61	-2.40	-1.60
EPS Growth %	-	-	0.38%	-0.65%	0%	0.08%	0.33%
EPS (Basic)	-0.01	-2.55	-1.59	-2.62	-2.61	-2.40	-1.60
Diluted Shares Outstanding	50.27M	8.98M	31.8M	32.86M	43.63M	49.01M	67.87M
Basic Shares Outstanding	50.27M	8.98M	31.8M	32.86M	43.63M	49.01M	67.87M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.23M	37.47M	318.83M	245.78M	360.69M	253.07M	273.34M
Cash & Short-Term Investments	7.87M	36.99M	314.91M	238.09M	352.14M	248.19M	267.35M
Cash Only	7.87M	20.61M	96.69M	60.82M	37.49M	31.04M	27.87M
Short-Term Investments	0	16.38M	218.22M	177.27M	314.65M	217.15M	239.48M
Accounts Receivable	150K	0	0	0	1.3M	200K	200K
Days Sales Outstanding	8.36	-	-	-	-	-	-
Inventory	117.29K	0	0	0	0	0	0
Days Inventory Outstanding	10.07	-	-	-	-	-	-
Other Current Assets	94.42K	66.51K	1.34M	3.15M	1.63M	1.42M	2.54M
Total Non-Current Assets+	1.38M	10.95M	18.82M	28.12M	112.25M	125.81M	227.87M
Property, Plant & Equipment	1.29M	10.22M	17.86M	24.53M	107.66M	119.28M	110.67M
Fixed Asset Turnover	5.09x	0.01x	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	89.81K	268.54K	0	0	2.74M	2.74M	110.39M
Other Non-Current Assets	0	455.08K	960K	3.59M	1.85M	3.8M	6.8M
Total Assets+	9.61M	48.41M	337.65M	273.9M	472.94M	378.88M	501.2M
Asset Turnover	0.68x	0.00x	-	-	-	-	-
Asset Growth %	-	4.04%	5.97%	-0.19%	0.73%	-0.2%	0.32%
Total Current Liabilities+	2.08M	8.21M	8.83M	12.94M	22.05M	23.33M	18.92M
Accounts Payable	367.17K	1.88M	1.18M	1.11M	1.76M	3.67M	638K
Days Payables Outstanding	31.52	39.9K	-	-	-	227.93	-
Short-Term Debt	0	0	0	0	4.25M	0	0
Deferred Revenue (Current)	0	1000K	0	0	0	0	0
Other Current Liabilities	408.44K	-857.45K	117K	96K	9.35M	6.72M	254K
Current Ratio	3.96x	4.56x	36.10x	18.99x	16.36x	10.85x	14.45x
Quick Ratio	3.91x	4.56x	36.10x	18.99x	16.36x	10.85x	14.45x
Cash Conversion Cycle	-13.09	-	-	-	-	-	-
Total Non-Current Liabilities+	12.92M	65.68M	7.6M	9.99M	78.69M	82.27M	74.31M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	5.78M	7.52M	9.97M	78.69M	82.27M	74.22M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	12.92M	59.9M	82K	18K	0	0	87K
Total Liabilities	15M	73.89M	16.43M	22.94M	100.73M	105.6M	93.23M
Total Debt+	12.71M	7.3M	8.92M	12.46M	82.93M	88.34M	80.27M
Net Debt	4.84M	-13.31M	-87.77M	-48.36M	45.44M	57.3M	52.4M
Debt / Equity	-	-	0.03x	0.05x	0.22x	0.32x	0.20x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-47.25x	-	-	-21.29x	-	-
Total Equity+	-5.4M	-25.48M	321.22M	250.97M	372.21M	273.29M	407.98M
Equity Growth %	-	-3.72%	13.61%	-0.22%	0.48%	-0.27%	0.49%
Book Value per Share	-0.11	-2.84	10.10	7.64	8.53	5.58	6.01
Total Shareholders' Equity	-5.4M	-25.48M	321.22M	250.97M	372.21M	273.29M	407.98M
Common Stock	123	160	3K	3K	5K	5K	7K
Retained Earnings	-5.58M	-26.66M	-118.02M	-204.1M	-317.93M	-435.43M	-544.22M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-244.75K	-2.14K	3K	-150K	-679K	8K	674K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.18M	-18.37M	-43.51M	-67.93M	-57M	-86.16M	-99.7M
Operating CF Margin %	-0.79%	-159.18%	-	-	-	-	-
Operating CF Growth %	-	-2.54%	-1.37%	-0.56%	0.16%	-0.51%	-0.16%
Net Income	-274.5K	-21.08M	-91.36M	-86.08M	-113.84M	-117.5M	-108.79M
Depreciation & Amortization	183.21K	401K	786K	1.76M	2.64M	5.87M	2.24M
Stock-Based Compensation	182.51K	947K	6.75M	14.46M	16.86M	17.2M	16.73M
Deferred Taxes	0	0	738K	3.24M	0	0	0
Other Non-Cash Items	548.94K	-818K	40.41M	337K	3.61M	-2.65M	2.29M
Working Capital Changes	-5.28M	2.18M	-828K	-1.64M	33.74M	10.93M	-12.16M
Change in Receivables	-14.82K	-463.26K	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	689.71K	2.64M	2.82M	2.79M	2.76M	4.22M	-4.47M
Cash from Investing+	-757.88K	-18.3M	-210.08M	32.53M	-184.69M	79.02M	-129.56M
Capital Expenditures	-757.88K	-1.93M	-7.51M	-5.03M	-47.11M	-28.15M	-4.41M
CapEx % of Revenue	0.12%	16.71%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	-202.57K	37.56K	-137.58K	0	0
Cash from Financing+	87.49K	49.58M	329.82M	1.2M	219.01M	691K	226.08M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	87.49K	-43.5M	-63.92M	0	1.84M	0	1.01M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-5.94M	-20.3M	-51.02M	-72.95M	-104.11M	-114.31M	-104.11M
FCF Margin %	-0.91%	-175.89%	-	-	-	-	-
FCF Growth %	-	-2.42%	-1.51%	-0.43%	-0.43%	-0.1%	0.09%
FCF per Share	-0.12	-2.26	-1.60	-2.22	-2.39	-2.33	-1.53
FCF Conversion (FCF/Net Income)	18.88x	0.87x	0.48x	0.79x	0.50x	0.73x	0.92x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-61.79%	-30.09%	-36.53%	-36.41%	-31.94%
Return on Invested Capital (ROIC)	-	-	-39.69%	-29.73%	-28.77%	-26.39%	-24.31%
Gross Margin	35.08%	85.08%	-	-	-	-	-
Net Margin	-4.19%	-18265.66%	-	-	-	-	-
Debt / Equity	-	-	0.03x	0.05x	0.22x	0.32x	0.20x
Interest Coverage	-	-47.25x	-	-	-21.29x	-	-
FCF Conversion	18.88x	0.87x	0.48x	0.79x	0.50x	0.73x	0.92x
Revenue Growth	-	-98.24%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Nkarta, Inc. (NKTX) grew revenue by 0.0% over the past year. Growth has been modest.

Nkarta, Inc. (NKTX) reported a net loss of $102.6M for fiscal year 2024.

Dividend & Returns

Nkarta, Inc. (NKTX) has a return on equity (ROE) of -31.9%. Negative ROE indicates the company is unprofitable.

Nkarta, Inc. (NKTX) had negative free cash flow of $93.6M in fiscal year 2024, likely due to heavy capital investments.